InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
2008年9月16日 - 10:15PM
PRニュース・ワイアー (英語)
- Biotech Begins to Demonstrate Strategy to Expand NHL Marketplace
with Novel Antibody and Speedy DXL Screening Preclinical
Development Program - BRITISH COLUMBIA, Canada, Sept. 16
/PRNewswire-FirstCall/ -- InNexus Biotechnology Inc. (TSX VENTURE:
IXS; OTC Bulletin Board: IXSBF; http://www.ixsbio.com/), a drug
development company commercializing the next generation of
monoclonal antibodies based on its technology, Dynamic Cross
Linking (DXL(TM)), announced today the results of an extensive
mouse tumor study demonstrating superiority of InNexus' DXL625
(CD20) versus Rituxan(R) in the xenograft model. InNexus plans to
submit the data for publication along with additional data from
animal studies recently completed and presented at the American
Association for Cancer Research (AACR) 2008 Annual Conference. The
company has also launched a large scale study of DXL625 with
primates, designed to evaluate toxicity and pharmokinetics,
enabling the company to move the product to the FDA toward human
testing. "A study performed by an independent group investigating
the survival of mice intravenously injected with B-lymphoma cells
and treated subsequently with DXL625 showed a significant
improvement in outcome compared to animals treated with equivalent
doses of Rituxan(R), a commercially available anti-CD20 antibody,"
said Dr. Thomas Kindt, InNexus' Chief Scientific Officer. "Animals
treated with either drug had a superior outcome when compared to
those receiving inactive control (vehicle), however DXL625 had a
substantial advantage over the competing antibody. We are confident
that these results will translate to therapeutic advantage when
DXL625 is used in human subjects." "The DXL(TM) technology platform
builds better antibodies and soon you'll be able to see our
strategy to expand the NHL marketplace. We enhance an antibody's
potency in a real, measurable and predictable fashion," said Jeff
Morhet, Chairman and Chief Executive Officer. "I'm pleased with our
scientific progress, regulatory plans and soon we'll be well
positioned to begin formal discussions with the FDA." About DXL(TM)
Technology Platform DXL(TM) technology works by integrating
self-binding peptides into monoclonal antibodies, potentiating
target binding. Modified antibodies "cluster" upon engaging the
target receptor site, resulting in greater "molecular mass" at the
point of association. DXL(TM) antibodies have significantly
extended dissociation rates, as measured by surface plasmon
resonance. As a consequence, this may facilitate cancer cell
destruction in a target dependent manner by increasing apoptosis,
antibody dependent cell cytotoxicity and complement-dependent
cytotoxicity. To learn more about InNexus' DXL(TM) technology,
please visit http://www.ixsbio.com/. About InNexus InNexus is a
drug development company commercializing the next generation of
monoclonal antibodies based on its DXL(TM) technology, which
improves the potency of new and existing antibody products while
opening new markets and disease applications. DXL(TM) antibodies
utilize unique, novel and patented methods and technologies of
InNexus. InNexus is headquartered in British Columbia with
principal management based in Scottsdale, Arizona on the campus of
Mayo Clinic and has its own in- house developmental facilities.
These development resources provide validation of protein and
peptide discoveries, enabling InNexus (and its strategic partners)
to advance novel drug therapeutics and diagnostics. To learn more
about InNexus, please visit http://www.ixsbio.com/. The TSX Venture
Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this news release. This news release
may contain assumptions, estimates, and other forward-looking
statements that involve inherent risks and uncertainties and are
subject to factors, many of which are beyond the Company's control
that may cause actual results or performance to differ materially
from those currently anticipated in such statements. DATASOURCE:
InNexus Biotechnology Inc. CONTACT: Jeff Morhet, Chairman &
Chief Executive Officer, +1-480-862-7500, or Dr. Thomas Kindt,
Chief Scientific Officer, +1-480-862-7500, both of InNexus
Biotechnology Inc. Web site: http://www.ixsbio.com/
Copyright